Mays Cancer Center at UT Health SA

UT Health SA 梅斯癌症中心

• 批准号: 10025094
• 负责人: Andrew Jacob Brenner
• 金额: $ 3.11万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10025094
• 关键词: Address; Adult; Agonist; Antidepressive Agents; Area; Basic Science; Bioinformatics; Biology; Biometry; Bladder Urothelium; Breast; Cancer Center; Cancer Etiology; Cancer Survivor; Catchment Area; Child; Childhood Malignant Brain Tumor; Clinical; Clinical Research; Clinical Trials; Collaborations; Conduct Clinical Trials; Dental; Development; Developmental Therapeutics Program; Doctor of Medicine; Doctor of Philosophy; Drug Combinations; Estrogen receptor positive; FDA approved; Funding; Glioblastoma; Goals; Grant; Growth; Health; Hypoxia; Immune response; Immunologic Markers; Immunooncology; Immunotherapy; Impaired cognition; Institutes; Intervention; Intervention Trial; Investigational Drugs; Investigational Therapies; Journals; Lead; Libraries; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Mass Spectrum Analysis; Medical; MicroRNAs; Modeling; Mus; Mutation; NCI-Designated Cancer Center; Natural Products; Obesity associated cancer; Patients; Peer Review; Peptides; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Physiological; Play; Preclinical Testing; Prediction of Response to Therapy; Prodrugs; Prostate; Publications; RNA; RNA methylation; RNA-Binding Proteins; Reporting; Research; Resource Sharing; Role; Schools; Scientist; Seminal; Signal Pathway; Sirolimus; Strategic Planning; T-Lymphocyte; Testing; Texas; Therapeutic; Therapeutic Agents; Tissues; Translational Research; Translations; Universities; Untranslated RNA; Work; aptamer; austin; base; cancer therapy; clinical development; drug development; drug discovery; drug structure; early phase clinical trial; genome-wide; high throughput screening; immunoregulation; improved; lead candidate; malignant mouth neoplasm; medulloblastoma; member; neuro-oncology; new therapeutic target; non-muscle invasive bladder cancer; novel; novel drug combination; novel therapeutics; programs; safety testing; small hairpin RNA; small molecule; structural biology; targeted treatment; therapeutic target; therapy resistant; translational physician; translational scientist; triple-negative invasive breast carcinoma; tumor; tumor immunology

Project Summary—Experimental and Developmental Therapeutics (EDT) Program The Experimental and Developmental Therapeutics (EDT) Program is one of three interactive research programs of the Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA). Andrew Brenner, M.D., Ph.D. and Manjeet Rao, Ph.D. serve as Co-Leaders of the EDT Program. The primary focus of the EDT Program is to improve treatment of cancer through basic, translational, and clinical research. The EDT Program is the hub for clinical development of discoveries made by all members of MCC. The EDT Program members have expertise spanning experimental and developmental therapeutics – from initial target discovery, to IND regulatory approval, to early-phase clinical trials. The EDT Program members pursue this research focused on three major themes: 1) Neuro-oncology; 2) Immuno-oncology; and 3) Drug repurposing. In addition to these major themes, the EDT Program has one emerging theme: Targeted therapeutics. EDT members will advance the translational potential within these themes through the following Specific Aims: 1) Discovery of novel targets; 2) Development of new therapeutic agents and approaches; and 3) Conduct of early-phase clinical trials of novel therapies. The EDT Program currently has 36 members, representing 13 departments within three schools (Medical, Dental and Graduate) at UT Health SA. Two members are from the University of Texas at Austin and one member from Texas State University. Fifteen members lead clinical trials. The EDT Program members have $5.7M of peer-reviewed cancer-related funding (27 grants). Of those, $2.7M are from 15 NCI grants. From January 2014 to June 2019, EDT Program members coauthored 414 peer-reviewed cancer-related publications, 24% were from intra-programmatic collaborations and 16% were from inter-programmatic collaborations. In addition, 79% of these publications involve multi-institutional collaborations, including 192 (46%) publications with other NCI-designated Cancer Centers. EDT members use all of the MCC-supported Shared Resources to pursue their cross-cutting research, especially the Biostatistics and Bioinformatics, Mass Spectrometry, Drug Discovery and Structural Biology facilities. EDT members have also led 130 interventional clinical trials, and in 2018 alone, 226 patients were accrued to intervention trials.

项目摘要-实验和开发治疗学（EDT）计划 实验和发展治疗学（EDT）计划是三个互动研究计划之一 Mays癌症中心（MCC）的研究人员在德克萨斯大学健康圣安东尼奥（UT Health SA）。安德鲁 布伦纳，医学博士，博士和Manjeet Rao博士担任EDT计划的联合领导人。的主要重点 EDT计划旨在通过基础、转化和临床研究来改善癌症的治疗。该能量检测 该计划是MCC所有成员发现的临床开发中心。EDT计划 成员拥有实验和开发治疗学的专业知识-从最初的靶点发现， 到IND监管批准，到早期临床试验。EDT计划成员进行这项研究 重点关注三大主题：1）神经肿瘤学; 2）免疫肿瘤学; 3）药物再利用。此外 除了这些主要的主题，EDT计划还有一个新的主题：靶向治疗。EDT成员将 通过以下具体目标推进这些主题中的翻译潜力：1）发现 新的目标; 2）开发新的治疗药物和方法; 3）进行早期临床研究 新疗法的试验。EDT计划目前有36名成员，代表三个部门内的13个部门。 学校（医学，牙科和研究生）在UT健康SA。两名成员来自德克萨斯大学， 奥斯汀和一名来自德克萨斯州立大学的成员。15名成员领导临床试验。EDT计划 成员们拥有570万美元的同行评审癌症相关资金（27笔赠款）。其中，270万美元来自15个NCI 赠款。从2014年1月到2019年6月，EDT计划成员共同撰写了414篇同行评审的癌症相关论文。 24%来自计划内合作，16%来自计划间合作 合作。此外，这些出版物中有79%涉及多机构合作，其中包括192 (46%）与其他NCI-designated癌症中心的出版物。EDT成员使用MCC支持的所有 共享资源，以追求他们的交叉研究，特别是生物统计学和生物信息学，马萨诸塞州 光谱、药物发现和结构生物学设施。EDT成员还领导了130个干预性的 仅在2018年，就有226名患者参加了干预试验。